Pathos Raises $237M Series C+ Led by Bristol Myers Squibb

Pathos Secures $237M Series C+ Round

Pathos, a clinical-stage, AI-enabled precision oncology biotech, has raised $237 million in a Series C+ funding round. The round was led by Bristol Myers Squibb, which was the sole investor listed in the transaction.

What Pathos Does

Pathos is building what it describes as the next generation of biopharma, where drug development is driven by AI and multimodal patient data rather than guesswork. The company states that it has the largest multimodal foundation model in oncology as a backbone.

Pathos runs an integrated engine that pairs model-driven hypotheses with biological validation and biomarker-driven clinical execution. The stated goal is to help the right therapies reach the right patients sooner.

Funding Details

• Company: Pathos
• Round type: Series C+
• Amount raised: $237,000,000 USD
• Funding date: October 23, 2026
• Lead investor: Bristol Myers Squibb
• Investors: Bristol Myers Squibb
• Company stage: Series C+

Why This Round Matters

The Series C+ designation indicates a follow-on to a prior Series C round, and the size of the raise places Pathos among the larger private financings in the AI-driven oncology space. The participation of Bristol Myers Squibb as lead investor is notable given the company's position as a global biopharma incumbent. For acquisition watchers, a strategic lead investor in a clinical-stage AI oncology platform is a signal worth tracking: corporate investors at this stage often build familiarity with a target's pipeline, data infrastructure, and clinical execution capabilities well ahead of any potential transaction.

What to Watch

Pathos describes itself as clinical-stage, meaning its programs have advanced into human testing. The company's differentiation rests on two pillars: a large multimodal foundation model in oncology, and an integrated engine that connects model-driven hypotheses to biological validation and biomarker-driven clinical execution. How those pillars translate into clinical readouts will be the key value driver for any future strategic conversation.

No additional investors, valuation, or use-of-proceeds details were disclosed in the funding information reviewed.